logo-loader
viewPressure BioSciences, Inc.

Zachs: Pressure BioSciences at 'tipping point,' initiates coverage with $4.44 target

Zachs is forecasting revenue of US$12.1 million by 2022, with 66% coming from instrument sales and the balance from consumables and contract services

CBD
Pressure BioSciences recently won two more customers for its water-soluble CBD manufacturing system, the BaroShear K4

Zachs Small-Cap Research has initiated coverage on Pressure BioSciences Inc (OTCMKTS:PBIO) with a price target of US$4.44 on the Massachusetts-based company.

Pressure BioSciences develops pressure-based platform technology solutions for the booming life sciences industry. Its key products are high pressure-based scientific instruments for drug design and development and the food science and CBD market.

During its second quarter, the firm saw strong consumables sales and serious momentum from the launch of its water-soluble CBD manufacturing system.

READ: Pressure BioSciences wins two more orders for its novel BaroShear K45 water-soluble CBD manufacturing system

In a research note, Zachs said that the firm was at a “tipping point,” with demand expected to accelerate starting in 2020.

“After a decade of marketing its original PCT sample preparation platform to academic opinion leaders and early research customers, the company recently launched two new proprietary technology platforms opening major new market opportunities,” Zachs analyst Elizabeth Senko wrote.

“In our view, the overall story is solid, and the combination of new platform products, new commercial applications, and customers position PBIO squarely to move its business to the next level.”

Zachs forecast revenue of US$12.1 million by 2022, with 66% coming from instrument sales and the balance from consumables and contract services.

The instrument manufacturer should reach operating profitability by 2022, according to Senko, as sales growth moves overhead costs from 140% of sales (in 2018) down to around 32%.

Pressure BioSciences recently won two more customers for its water-soluble CBD manufacturing system, the BaroShear K45, which applies high-pressure to create nano-scale emulsion mixtures that results in stable homogenized products called nanoemulsions.

Shares of Pressure BioSciences inched 0.8% higher on Friday afternoon to trade at US$2.67.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Pressure BioSciences, Inc.

Price: 2.32 USD

OTCMKTS:PBIO
Market: OTCQB
Market Cap: $5.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

on 10/04/2019

2 min read